Lipocine to Present at 2016 Ladenburg Thalmann Healthcare Conference
September 20 2016 - 8:00AM
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company,
today announced that Mahesh Patel, President and CEO, and Morgan
Brown, Executive Vice President and CFO, will present a company
overview at the 2016 Ladenburg Thalmann Healthcare Conference on
Tuesday, September 27, 2016 at 11:00 a.m. ET.
A live audio webcast of the presentation will be available via
the "Investor Relations" page of the Lipocine website,
www.lipocine.com. Please log on through Lipocine's website
approximately 10 minutes prior to the scheduled start time. A
replay of the webcast will also be archived on Lipocine's website
for 90 days following the presentation.
About Lipocine
Lipocine Inc. is a specialty pharmaceutical company developing
innovative pharmaceutical products for use in men's and women's
health using its proprietary drug delivery technologies. LPCN 1021,
an oral testosterone replacement therapy product candidate,
demonstrated positive efficacy and safety results in Phase 3
testing but received a Complete Response Letter from the FDA on
June 28, 2016. LPCN 1111, a next-generation oral testosterone
replacement therapy product with once-daily dosing, is currently in
Phase 2 testing. LPCN 1107, which has the potential to become the
first oral hydroxyprogesterone caproate product indicated for the
prevention of recurrent preterm birth, had an End of Phase 2
meeting with the FDA during the third quarter of 2016 and has been
granted orphan drug designation by the FDA. For more information,
please visit www.lipocine.com.
Forward-Looking Statements
This release contains “forward looking statements” that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and include statements that are not
historical facts relating to Lipocine’s FDA review process relating
to LPCN 1021 and the possible outcome of such process, clinical
trials, the regulatory process for our other product candidates,
the potential uses and benefits of our product candidates, the TRT
market, product development and commercialization efforts and the
projected timing and outcome of regulatory filings and actions.
Investors are cautioned that all such forward-looking statements
involve risks and uncertainties, including, without limitation, the
risks related to our products, expected product benefits, clinical
and regulatory expectations and plans, regulatory developments and
requirements, risks related to the receipt of a CRL from the FDA
for LPCN 1021, the receipt of regulatory approvals, the results of
clinical trials, patient acceptance of Lipocine’s products, the
manufacturing and commercialization of Lipocine’s products, the
risks related to market conditions for Lipocine’s common stock and
other risks detailed in Lipocine’s filings with the SEC, including,
without limitation, its Form 10-K and other reports on Forms 8-K
and 10-Q, all of which can be obtained on the SEC website at
www.sec.gov. Lipocine assumes no obligation to update or revise
publicly any forward-looking statements contained in this release,
except as required by law.
CONTACT:
Morgan Brown
Executive Vice President & Chief Financial Officer
Phone: (801) 994-7383
mb@lipocine.com
Investors:
John Woolford
Phone: (443) 213-0506
john.woolford@westwicke.com
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Apr 2023 to Apr 2024